1239908-20-3

MLN2238 rapidly hydrolyzes to MLN2238, which is a selective, orally bioavailable, second-generation proteasome inhibitor, inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with an IC50 value of 3.4 nM (Ki of 0.93 nM), and also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites with IC50 of 31 and 3500 nM, respectively.